Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.46 |
| ▸ | CDK2 | P24941 | 6/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.46 |
| ▸ | INSR | P06213 | 3/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372012 | 0.92 | IGF1R (0.66) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1373562 | 0.91 | IGF1R (0.64) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1370834 | 0.91 | IGF1R (0.66) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1374061 | 0.90 | IGF1R (0.79) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL4282762 | 0.90 | IGF1R (0.64) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1373755 | 0.90 | IGF1R (0.66) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1374377 | 0.90 | IGF1R (0.64) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1373844 | 0.89 | IGF1R (0.63) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1370506 | 0.89 | IGF1R (0.60) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1370806 | 0.89 | IGF1R (0.61) | IGF1RNTRK1NTRK3NTRK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.I. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7968583-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885NTRK1 1363/4885NTRK3 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.